BioPharm International

BioPharm International September October 2026
Volume: 39
Issue: 5

Formulation Advances 2026 eBook
Volume: 39

BioPharm International July August 2026
Volume: 39
Issue: 4

Quality and Regulations 2026 eBook
Volume: 39

BioPharm International Trends in Manufacturing eBook May 2026
Volume: 39

BioPharm International May June 2026
Volume: 39
Issue: 3

BioPharm International March April 2026
Volume: 39
Issue: 2

Bio/Pharma Outsourcing Innovation eBook
Volume: 39

BioPharm International January February 2026
Volume: 39
Issue: 1

Novel Delivery Approaches of Biopharmaceuticals 2025
Volume: 38

BioPharm International November December 2025
Volume: 38
Issue: 8

Trends in Formulation October 2025 eBook
Volume: 38

BioPharm International September October 2025
Volume: 38
Issue: 7

Quality and Regulations 2025 eBook
Volume: 38

BioPharm International July August 2025
Volume: 38
Issue: 6

BioPharm International June 2025
Volume: 38
Issue: 5

Trends in Manufacturing eBook, May 2025

BioPharm International May 2025
Volume: 38
Issue: 4

BioPharm International April 2025
Volume: 38
Issue: 3

Next-Generation Biotherapeutics eBook April 2025
Volume: 38
Issue: 2

BioPharm International, March 2025
Volume: 38
Issue: 2

BIo/Pharma Outsourcing Innovation eBook February 2025
Volume: 38
Issue: 1

BioPharm International, JanuaryFebruary 2025
Volume: 38
Issue: 1

BioPharm International, November-December 2024
Volume: 37
Issue: 10

BioPharm International, Manufacturing and Facilities eBook November 2024
Volume: 37
Issue: 4

BioPharm International, October 2024
Volume: 37
Issue: 9

BioPharm International, September 2024
Volume: 37
Issue: 8

BioPharm International, Emerging Therapies eBook September 2024
Volume: 37
Issue: 3

BioPharm International, July August 2024
Volume: 37
Issue: 7

BioPharm International, June 2024
Volume: 37
Issue: 6
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
3
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
4
FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis
5

